Genoa Ventures
Venture Capital
Active
San Francisco, United States
33
18M
25
3.30
9
0.24
3
- Stages of investment
- Areas of investment
Summary
In 2014 was created Genoa Ventures, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the San Francisco.
The fund was created by Jenny Rooke.
The top activity for fund was in 2017. Considering the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Genoa Ventures works on 21 percentage points less the average amount of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually.
Among the most popular portfolio startups of the fund, we may highlight Zymergen, Caribou Biosciences, Akadeum Life Sciences. Among the most popular fund investment industries, there are Pharmaceutical, Biopharma. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Genoa Ventures, startups are often financed by Cultivation Capital, Serra Ventures, Novartis. The meaningful sponsors for the fund in investment in the same round are Jenny Rooke, True Ventures, Shu Duan. In the next rounds fund is usually obtained by Threshold, Innovation Endeavors, Data Collective DCVC.
Investor highlights
- Industry focus
- Stage focus
- Check size
- 1M — 5M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 84000000
- Fund raised date
- 2022-07-28
Analytics
- Total investments
- 33
- Lead investments
- 9
- Exits
- 3
- Rounds per year
- 3.30
- Follow on index
- 0.24
- Investments by industry
- Biotechnology (30)
- Health Care (15)
- Life Science (7)
- Medical (6)
- Health Diagnostics (6) Show 31 more
- Investments by region
-
- United States (31)
- United Kingdom (1)
- France (1)
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 76M
- Group Appearance index
- 0.82
- Avg. company exit year
- 4
- Strategy success index
- 0.20
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Alida Biosciences | 12 Jun 2024 | Biotechnology, Health Care, Life Science | Early Stage Venture | 7M | United States, California, San Diego |
| Pear Chef | 01 Jan 2019 | Seed | United States, Illinois, Chicago | ||
| SimBioSys | 26 Oct 2021 | Biotechnology, Life Science, Pharmaceutical | Early Stage Venture | 15M | United States, Illinois, Champaign |
| Trax | 01 Jun 2011 | E-Commerce, Analytics, Retail Technology, Computer Vision, Image Recognition | Seed | 1M | Central, Singapore, Singapore |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.